Melatonin Inhibits Antibody‐Secreting Cells and Improves Systemic Lupus Erythematosus via Modulation of the PKA‐CREB Signaling Pathway
Journal of Pineal Research · 2025
DOI: 10.1111/jpi.70093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pineal Research, 2025. Verfasst von Pei Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Human Key Laboratory of Medical Epigenomics, the Second Xiangya Hospital, Central South University, Changsha, 410011, Chin…. Hauptthemen laut MEDLINE: Melatonin, Lupus Erythematosus, Systemic, Signal Transduction, Cyclic AMP-Dependent Protein Kinases. Die Arbeit nennt 61 Literaturangaben.
Abstract (Originalsprache)
Systemic lupus erythematosus (SLE) is an autoimmune disorder featuring abnormal B cell differentiation and excessive autoantibody production, leading to multiorgan damage. Despite advances in understanding SLE pathogenesis, the molecular mechanisms driving aberrant B cell differentiation remain elusive. Melatonin, a neuroendocrine hormone with immunomodulatory properties, has been shown to regulate immune responses, but its role in B cell differentiation and SLE is poorly understood. This study investigates the role of melatonin and its receptors in B cell differentiation and SLE pathogenesis. We observed reduced serum melatonin levels and decreased expression of melatonin receptors in B cells from SLE patients and MRL/Lpr mice. Activation of melatonin receptors inhibited the protein kinase A (PKA) signaling pathway and reduced phosphorylation of cyclic‐AMP response binding protein (CREB), leading to epigenetic downregulation of PRDM1 and IRF4, key transcription factors for plasmablast and plasma cell differentiation. Consequently, melatonin receptor activation suppressed abnormal B cell differentiation into antibody‐secreting cells. Our findings highlight melatonin and its receptor signaling as potential therapeutic targets for SLE and other autoimmune diseases mediated by aberrant antibody‐secreting cell activity. This study provides novel insights into the protective role of melatonin in SLE and offers a promising avenue for developing targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Human Key Laboratory of Medical Epigenomics, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
- Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, 210042, China.
- Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, 210042, China.
- Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410011, China.
ORCID-Profile: Ming Zhao
Zitieren
APA
Du, P., Yu, Y., Zhang, W., Sun, K., He, W., Zhao, M., & Jia, S. (2025). Melatonin Inhibits Antibody‐Secreting Cells and Improves Systemic Lupus Erythematosus via Modulation of the PKA‐CREB Signaling Pathway. Journal of Pineal Research. https://doi.org/10.1111/jpi.70093
Vancouver
Du P, Yu Y, Zhang W, Sun K, He W, Zhao M, et al. Melatonin Inhibits Antibody‐Secreting Cells and Improves Systemic Lupus Erythematosus via Modulation of the PKA‐CREB Signaling Pathway. Journal of Pineal Research. 2025. doi:10.1111/jpi.70093
BibTeX
@article{Du2025,
author = {Du, Pei and Yu, Yaqin and Zhang, Wenqian and Sun, Ke and He, Wei and Zhao, Ming and Jia, Sujie},
title = {Melatonin Inhibits Antibody‐Secreting Cells and Improves Systemic Lupus Erythematosus via Modulation of the PKA‐CREB Signaling Pathway},
journal = {Journal of Pineal Research},
year = {2025},
doi = {10.1111/jpi.70093}
}
EUVIMED